Absci to Present Preclinical Data for ABS-101, A Potential Best-in-Class Anti-TL1A Antibody Development Program, at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 07:00 ET
|
Absci Corporation
Preclinical data support profile for development of a potential best-in-class drug IND submission expected in Q1 2025; Phase 1 trials anticipated to initiate shortly after VANCOUVER, Wash....
Absci to Participate in the 26th Annual Needham Growth Conference
January 03, 2024 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Jan. 03, 2024 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating virtually...
Absci to Participate in the 42nd Annual J.P. Morgan Healthcare Conference
December 28, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Dec. 28, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the...
Absci and PrecisionLife Announce Strategic R&D Partnership to Jointly Develop AI-Enabled Drug Pipeline
December 20, 2023 07:30 ET
|
Absci Corporation
Leading AI biologics and precision medicine innovators will harness technologies to build a diverse portfolio of novel drug treatments With this partnership, Absci achieves 2023 outlook of ten...
Absci Announces Collaboration with AstraZeneca to Advance AI-Driven Oncology Candidate
December 04, 2023 07:30 ET
|
Absci Corporation
VANCOUVER, Wash., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a leader in generative AI antibody discovery, today announced a collaboration with AstraZeneca, a global...
Absci to Participate in the Piper Sandler 35th Annual Healthcare Conference
November 15, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Nov. 15, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the...
Absci Reports Business Updates and Third Quarter 2023 Financial and Operating Results
November 14, 2023 16:05 ET
|
Absci Corporation
Entered into partnership with Almirall to rapidly develop novel treatments for dermatological diseases, for up to $664M in deal value, plus royalties Unveiled AI drug creation pipeline of four...
Almirall and Absci announce AI drug discovery partnership to rapidly develop novel treatments for dermatological diseases
November 14, 2023 02:05 ET
|
Absci Corporation
VANCOUVER, Wash. and BARCELONA, Spain, Nov. 14, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and Almirall S.A. (BME: ALM), a global...
Absci to Participate in Upcoming Investor Conferences
October 26, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the company will be participating in the...
Absci Announces Speaker Lineup for Inaugural R&D Day, Including Renowned Global Business Leader Sandi Peterson and VP of Applied Research at NVIDIA Jonathan Cohen
September 21, 2023 08:00 ET
|
Absci Corporation
VANCOUVER, Wash. and NEW YORK, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, today announced the speaker lineup for its inaugural...